Department of Otolaryngology - Head and Neck Surgery, United States; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, United States.
Department of Otolaryngology - Head and Neck Surgery, United States; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, United States.
Oral Oncol. 2018 Nov;86:200-205. doi: 10.1016/j.oraloncology.2018.09.026. Epub 2018 Oct 1.
Organ preservation protocols utilizing induction chemotherapy as a selection agent have played a critical role in the treatment of advanced laryngeal squamous cell carcinoma (LSCC). The selection of patients who will have a good response to chemoradiation allows for organ preservation in a significant group of patients and minimizes the rate of surgical salvage. While there remains debate regarding its utility when compared to surgery or other organ preservation regimens, the data does suggest an important role for induction chemotherapy in LSCC. In addition, there are continued opportunities to identify pretreatment biomarkers for induction chemotherapy, whether genetic, epigenetic or cellular, that could predict response to treatment and select patients to therapy (whether organ preservation or surgery). As our understanding of the biology of larynx cancer advances, induction paradigms have utility for the development and adoption of novel agents and therapeutics. The background of induction chemotherapy as a selection agent and future directions of this approach are discussed.
利用诱导化疗作为选择剂的器官保存方案在治疗晚期喉鳞状细胞癌（LSCC）中发挥了关键作用。选择对放化疗反应良好的患者可以使相当一部分患者保留器官，并最大限度地降低手术挽救的几率。虽然与手术或其他器官保存方案相比，其效用仍存在争议，但数据确实表明诱导化疗在 LSCC 中具有重要作用。此外，仍然有机会确定诱导化疗的预处理生物标志物，无论是遗传、表观遗传还是细胞的，这些都可以预测治疗反应并选择患者进行治疗（无论是器官保存还是手术）。随着我们对喉癌生物学的理解不断深入，诱导方案可用于开发和采用新的药物和疗法。本文讨论了诱导化疗作为选择剂的背景以及该方法的未来方向。
